Mirum Pharmaceuticals stock (US60471A1034): Hits all-time high amid $600M debt deal

Mirum Pharmaceuticals shares reached an all-time high of $112.47 recently, before dropping on news of a $600 million convertible notes offering announced May 12, 2026.

Mirum Pharmaceuticals stock surged to an all-time high of $112.47, reflecting strong momentum in 2026 with shares up 38.2% year-to-date from $78.99 on January 1, according to MarketBeat as of 05/13/2026. The biopharma company's NASDAQ-listed shares closed at $109.16 on May 13, up 2.13%, but dipped 2% to $104.64 in extended trading after pricing a $600 million convertible senior notes offering on May 12, per Sahm Capital as of 05/12/2026. The notes carry an initial conversion price at a 30% premium to the $106.88 closing price that day, as detailed in the company's announcement via Lelezard as of May 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Mirum Pharmaceuticals, Inc.
• Sector/industry: Medical / Biotechnology
• Headquarters/country: United States
• Core markets: Rare liver diseases
• Key revenue drivers: Therapies for cholestatic diseases
• Home exchange/listing venue: Nasdaq (MIRM)
• Trading currency: USD

Mirum Pharmaceuticals: core business model

Mirum Pharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare cholestatic liver diseases, as stated on its overview via MarketBeat as of 05/13/2026. Founded in 2018 and headquartered in the US, the firm targets unmet needs in pediatric and adult patients with conditions like Alagille syndrome and progressive familial intrahepatic cholestasis. Its lead product, Livmarli, is an approved oral therapy that has driven initial commercialization efforts.

The company's pipeline emphasizes innovative treatments for liver disorders, with a market cap reaching $6.66 billion as of May 13, 2026, per MarketBeat data. Mirum employs 140 people and operates primarily in the US market, making it relevant for American investors tracking biotech growth in rare disease segments.

Main revenue and product drivers for Mirum Pharmaceuticals

Livmarli remains the primary revenue driver, approved for cholestatic pruritus in Alagille syndrome patients one year and older, contributing to the company's commercial footprint since its 2021 launch. Recent stock gains underscore investor confidence in this franchise amid expanding indications, with shares hitting $112.47 all-time high as reported by Investing.com.

Pipeline candidates target additional rare liver diseases, supporting long-term growth. The $600 million convertible notes issuance on May 12, 2026, priced at a 30% premium to $106.88, provides capital for these advancements without immediate dilution, according to the pricing announcement.

Industry trends and competitive position

The rare disease biotech sector has seen robust US market interest, with firms like Mirum benefiting from accelerated approvals and orphan drug incentives. Mirum's focus on cholestatic liver therapies positions it in a niche with limited competition, enhancing its appeal to US investors seeking exposure to high-growth biopharma subsectors.

Why Mirum Pharmaceuticals matters for US investors

Listed on Nasdaq under MIRM, Mirum offers US investors direct access to innovative rare disease treatments amid a favorable regulatory environment from the FDA. Its $6.66 billion market cap and 38.2% YTD gain as of May 13, 2026, highlight momentum in the US biotech landscape.

Conclusion

Mirum Pharmaceuticals has delivered impressive share price performance in 2026, culminating in an all-time high before the recent convertible debt announcement. With a solid rare disease focus and Nasdaq listing, it remains a notable name in US biotech. Investors track upcoming milestones amid ongoing pipeline progress.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.